Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
This report contains market size and forecasts of Tyrosine Kinase JAK Inhibitors in global, including the following market information:
Global Tyrosine Kinase JAK Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Tyrosine Kinase JAK Inhibitors Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Tyrosine Kinase JAK Inhibitors companies in 2021 (%)
The global Tyrosine Kinase JAK Inhibitors market was valued at 31360 million in 2021 and is projected to reach US$ 497670 million by 2028, at a CAGR of 48.4% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tofacitinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tyrosine Kinase JAK Inhibitors include Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie and Vertex, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Tyrosine Kinase JAK Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tyrosine Kinase JAK Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tyrosine Kinase JAK Inhibitors Market Segment Percentages, by Type, 2021 (%)
Tofacitinib
Ruxolitinib
Baricitinib
Global Tyrosine Kinase JAK Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tyrosine Kinase JAK Inhibitors Market Segment Percentages, by Application, 2021 (%)
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
Global Tyrosine Kinase JAK Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tyrosine Kinase JAK Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tyrosine Kinase JAK Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Tyrosine Kinase JAK Inhibitors revenues share in global market, 2021 (%)
Key companies Tyrosine Kinase JAK Inhibitors sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Tyrosine Kinase JAK Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma

LEAVE A REPLY

Please enter your comment!
Please enter your name here